177 related articles for article (PubMed ID: 14625300)
21. Identification of ectodomain regions contributing to gating, deactivation, and resensitization of purinergic P2X receptors.
Zemkova H; He ML; Koshimizu TA; Stojilkovic SS
J Neurosci; 2004 Aug; 24(31):6968-78. PubMed ID: 15295032
[TBL] [Abstract][Full Text] [Related]
22. Competitive antagonism of recombinant P2X(2/3) receptors by 2', 3'-O-(2,4,6-trinitrophenyl) adenosine 5'-triphosphate (TNP-ATP).
Burgard EC; Niforatos W; van Biesen T; Lynch KJ; Kage KL; Touma E; Kowaluk EA; Jarvis MF
Mol Pharmacol; 2000 Dec; 58(6):1502-10. PubMed ID: 11093790
[TBL] [Abstract][Full Text] [Related]
23. Agonist-dependence of recovery from desensitization of P2X(3) receptors provides a novel and sensitive approach for their rapid up or downregulation.
Sokolova E; Skorinkin A; Fabbretti E; Masten L; Nistri A; Giniatullin R
Br J Pharmacol; 2004 Mar; 141(6):1048-58. PubMed ID: 14980981
[TBL] [Abstract][Full Text] [Related]
24. Experimental and modeling studies of desensitization of P2X3 receptors.
Sokolova E; Skorinkin A; Moiseev I; Agrachev A; Nistri A; Giniatullin R
Mol Pharmacol; 2006 Jul; 70(1):373-82. PubMed ID: 16627751
[TBL] [Abstract][Full Text] [Related]
25. The suramin analogue NF279 is a novel and potent antagonist selective for the P2X(1) receptor.
Rettinger J; Schmalzing G; Damer S; Müller G; Nickel P; Lambrecht G
Neuropharmacology; 2000 Aug; 39(11):2044-53. PubMed ID: 10963748
[TBL] [Abstract][Full Text] [Related]
26. ATP binding at human P2X1 receptors. Contribution of aromatic and basic amino acids revealed using mutagenesis and partial agonists.
Roberts JA; Evans RJ
J Biol Chem; 2004 Mar; 279(10):9043-55. PubMed ID: 14699168
[TBL] [Abstract][Full Text] [Related]
27. Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors.
Kim YC; Brown SG; Harden TK; Boyer JL; Dubyak G; King BF; Burnstock G; Jacobson KA
J Med Chem; 2001 Feb; 44(3):340-9. PubMed ID: 11462975
[TBL] [Abstract][Full Text] [Related]
28. Selectivity of diadenosine polyphosphates for rat P2X receptor subunits.
Wildman SS; Brown SG; King BF; Burnstock G
Eur J Pharmacol; 1999 Feb; 367(1):119-23. PubMed ID: 10082274
[TBL] [Abstract][Full Text] [Related]
29. Trinitrophenyl-substituted nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2/3 receptors.
Virginio C; Robertson G; Surprenant A; North RA
Mol Pharmacol; 1998 Jun; 53(6):969-73. PubMed ID: 9614197
[TBL] [Abstract][Full Text] [Related]
30. Dual presynaptic control by ATP of glutamate release via facilitatory P2X1, P2X2/3, and P2X3 and inhibitory P2Y1, P2Y2, and/or P2Y4 receptors in the rat hippocampus.
Rodrigues RJ; Almeida T; Richardson PJ; Oliveira CR; Cunha RA
J Neurosci; 2005 Jul; 25(27):6286-95. PubMed ID: 16000618
[TBL] [Abstract][Full Text] [Related]
31. P2X receptors in mouse Leydig cells.
Poletto Chaves LA; Pontelli EP; Varanda WA
Am J Physiol Cell Physiol; 2006 Apr; 290(4):C1009-17. PubMed ID: 16291815
[TBL] [Abstract][Full Text] [Related]
32. Functional evidence that ATP or a related purine is an inhibitory NANC neurotransmitter in the mouse jejunum: study on the identity of P2X and P2Y purinoceptors involved.
De Man JG; De Winter BY; Seerden TC; De Schepper HU; Herman AG; Pelckmans PA
Br J Pharmacol; 2003 Nov; 140(6):1108-16. PubMed ID: 14530212
[TBL] [Abstract][Full Text] [Related]
33. High affinity P2x-purinoceptor binding sites for [35S]-adenosine 5'-O-[3-thiotriphosphate] in rat vas deferens membranes.
Michel AD; Humphrey PP
Br J Pharmacol; 1996 Jan; 117(1):63-70. PubMed ID: 8825344
[TBL] [Abstract][Full Text] [Related]
34. Heteromultimerization modulates P2X receptor functions through participating extracellular and C-terminal subdomains.
Koshimizu TA; Ueno S; Tanoue A; Yanagihara N; Stojilkovic SS; Tsujimoto G
J Biol Chem; 2002 Dec; 277(49):46891-9. PubMed ID: 12361958
[TBL] [Abstract][Full Text] [Related]
35. Activation of Prejunctional P2x2/3 Heterotrimers by ATP Enhances the Cholinergic Tone in Obstructed Human Urinary Bladders.
Silva-Ramos M; Silva I; Faria M; Ferreirinha F; Correia-de-Sá P
J Pharmacol Exp Ther; 2020 Jan; 372(1):63-72. PubMed ID: 31636173
[TBL] [Abstract][Full Text] [Related]
36. Characterisation of ATP analogues to cross-link and label P2X receptors.
Agboh KC; Powell AJ; Evans RJ
Neuropharmacology; 2009 Jan; 56(1):230-6. PubMed ID: 18599093
[TBL] [Abstract][Full Text] [Related]
37. Sensitization by extracellular Ca(2+) of rat P2X(5) receptor and its pharmacological properties compared with rat P2X(1).
Wildman SS; Brown SG; Rahman M; Noel CA; Churchill L; Burnstock G; Unwin RJ; King BF
Mol Pharmacol; 2002 Oct; 62(4):957-66. PubMed ID: 12237343
[TBL] [Abstract][Full Text] [Related]
38. Modulatory activity of extracellular H+ and Zn2+ on ATP-responses at rP2X1 and rP2X3 receptors.
Wildman SS; King BF; Burnstock G
Br J Pharmacol; 1999 Sep; 128(2):486-92. PubMed ID: 10510462
[TBL] [Abstract][Full Text] [Related]
39. The P2X3 antagonist P1, P5-di[inosine-5'] pentaphosphate binds to the desensitized state of the receptor in rat dorsal root ganglion neurons.
Ford KK; Matchett M; Krause JE; Yu W
J Pharmacol Exp Ther; 2005 Oct; 315(1):405-13. PubMed ID: 16014755
[TBL] [Abstract][Full Text] [Related]
40. Metabotropic P2Y receptors inhibit P2X3 receptor-channels via G protein-dependent facilitation of their desensitization.
Gerevich Z; Zadori Z; Müller C; Wirkner K; Schröder W; Rubini P; Illes P
Br J Pharmacol; 2007 May; 151(2):226-36. PubMed ID: 17351651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
